Goldman Sachs’s Drugs Made In America Acquisition Corp DMAA Stock Holding History

Goldman Sachs’s Portfolio DMAA Stock Details DMAA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-119,686	Closed	-$1.25M	–	7143
2026 Q1	$1.25M	Hold	119,686	–	–	﹤0.01%	4921
2025 Q4	$1.24M	Hold	119,686	–	–	﹤0.01%	4967
2025 Q3	$1.23M	Hold	119,686	–	–	﹤0.01%	4885
2025 Q2	$1.22M	Hold	119,686	–	–	﹤0.01%	4545
2025 Q1	$1.2M	Buy	+119,686	New	+$1.2M	﹤0.01%	4544

Other funds holding DMAA

Karpus Investment Management Pittsford, New York $3.48B AUM 10.49% 1-Year Est. Return

Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return

Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return

Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return

Goldman Sachs's DMAA Position: Q2 2026 in Review

Goldman Sachs sold out of Drugs Made In America Acquisition Corp (DMAA) in Q2 2026, closing a stake of 119,686 shares — an estimated $1.25M sold.

Goldman Sachs first reported a position in DMAA in Q1 2025 and held it in 5 quarters. The position peaked at $1.25M in Q1 2026. 23 funds tracked by Wall St. Rank hold DMAA as of Q2 2026.

Goldman Sachs reported no remaining Drugs Made In America Acquisition Corp position as of Q2 2026 after selling out during the quarter.
Goldman Sachs sold 119,686 Drugs Made In America Acquisition Corp shares in Q2 2026, an estimated $1.25M.
Goldman Sachs first reported a position in Drugs Made In America Acquisition Corp in Q1 2025 and held it in 5 quarters.
Goldman Sachs's Drugs Made In America Acquisition Corp position peaked at $1.25M in Q1 2026.
23 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.